Jun 26, 2023 | Psychedelics
FDA discloses its first draft guidance on psychedelic trials The US Food and Drug Administration (FDA) has released its first draft guidance on clinical trials investigating psychedelic drugs. The agency aims to provide fundamental considerations for researchers...
Jun 26, 2023 | Psychedelics
Three In Five American Voters Support Legalizing Psychedelic Therapy, And Half Want To End Criminalization Altogether, New Poll Finds About three in five American voters say psychedelics should be legalized for regulated, therapeutic use—and nearly half believe...
Jun 23, 2023 | Psychedelics
Mindset Pharma Receives Approval for Phase II Depression Trial Mindset Pharma has been granted approval to start a Phase 2 trial for Major Depressive Disorder, using their lead drug candidate MSP-1014 MSP-1014 is a novel prodrug of psilocin, the active metabolite of...
Jun 23, 2023 | Psychedelics
FDA Releases First-Ever Draft Guidance For Psychedelics Research, Days After Congressional Lawmakers File Bill Asking For It The Food and Drug Administration (FDA) has released first-of-its-kind draft guidance on the “unique” considerations that researchers should...
Jun 21, 2023 | Psychedelics
Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access. In an interview with MarketWatch, Mycoskie said the money will help fund...
Jun 21, 2023 | Psychedelics
New Study Shows Psychedelics Associated With Decrease Use of Other Substances A new study shows that psychedelic use was associated with a decreased use of other drugs and substances. The research paper, entitled Changed Substance Use After Psychedelic Experiences...
